diazooxonorleucine and Carcinoma, Pancreatic Ductal

diazooxonorleucine has been researched along with Carcinoma, Pancreatic Ductal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Banerjee, S; Dudeja, V; Durden, BC; Ferrantella, A; Garrido, VT; Giri, B; Gupta, VK; Hadad, R; Kesh, K; Saluja, A; Sharma, NS	1

Other Studies

1 other study(ies) available for diazooxonorleucine and Carcinoma, Pancreatic Ductal

Article	Year
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. The Journal of clinical investigation, 2020, 01-02, Volume: 130, Issue:1 Topics: Animals; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Diazooxonorleucine; Female; Hexosamines; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Xenograft Model Antitumor Assays	2020

Article

Year

Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

The Journal of clinical investigation, 2020, 01-02, Volume: 130, Issue:1

Topics: Animals; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Diazooxonorleucine; Female; Hexosamines; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Xenograft Model Antitumor Assays

2020